KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Change in Receivables: 2014-2024

Historic Change in Receivables for Travere Therapeutics (TVTX) over the last 11 years, with Dec 2024 value amounting to $6.0 million.

  • Travere Therapeutics' Change in Receivables rose 5940.36% to $44.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $57.6 million, marking a year-over-year increase of 380.77%. This contributed to the annual value of $6.0 million for FY2024, which is 46.72% down from last year.
  • According to the latest figures from FY2024, Travere Therapeutics' Change in Receivables is $6.0 million, which was down 46.72% from $11.3 million recorded in FY2023.
  • In the past 5 years, Travere Therapeutics' Change in Receivables ranged from a high of $11.3 million in FY2023 and a low of -$2.3 million during FY2020.
  • Over the past 3 years, Travere Therapeutics' median Change in Receivables value was $6.0 million (recorded in 2024), while the average stood at $6.1 million.
  • Per our database at Business Quant, Travere Therapeutics' Change in Receivables plummeted by 144.39% in 2020 and then soared by 962.64% in 2023.
  • Over the past 5 years, Travere Therapeutics' Change in Receivables (Yearly) stood at -$2.3 million in 2020, then spiked by 62.93% to -$853,000 in 2021, then surged by 224.27% to $1.1 million in 2022, then skyrocketed by 962.64% to $11.3 million in 2023, then crashed by 46.72% to $6.0 million in 2024.